A recent report by Transgenomic Inc. has announced that their Clopidogrel Genetic Absorption Activation Panel or C-GAAP or Plavix response test will be covered by Medicare Plans . Transgenomic’s test recognizes dissimilarity in the ABCB1 and CYP2C19 genes, the presence of which signals a considerable chance that a patient will not respond properly to Plavix. The exclusiveness of Transgenomic’s test is due to the fact that it is the only one which also tests for difference in the ABCB1 gene.
An anti-blood clotting drug, Plavix, is a drug sold by Bristol-Myers and Sanofi-Aventis and prescribed to patients to lessen the risk of heart attack, stroke or cardiovascular death. Plavix lost patent individuality in May 2012, permitting generic versions to enter the U.S. market. This is projected to boost uptake of the drug even more and result in even bigger demand for Plavix response testing.
The recent news about Medicare coverage for the use of C-GAAP may facilitate the progress of Transgenomic’s awareness-driving efforts and will surely improve the likelihood that physicians will use it.
For more information please visit us @ www.medigap4seniors.com, , or call us at 888-502-5553 to speak with one of our Medicare experts.